These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9395815)

  • 21. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
    Sebastian M; Makkar R
    Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
    Zeymer U
    Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review.
    Anne G; Gruberg L
    Expert Opin Pharmacother; 2004 Feb; 5(2):335-48. PubMed ID: 14996630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.
    Tan HC; Harrington RA; Tcheng JE
    J Thromb Thrombolysis; 1997; 4(3/4):431-439. PubMed ID: 10639648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
    J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction.
    Colombo A; Briguori C
    Am Heart J; 1999 Aug; 138(2 Pt 2):S153-7. PubMed ID: 10426875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review.
    Truong KM; Amankwa K; Kucukarslan S
    Clin Ther; 2001 Aug; 23(8):1145-65; discussion 1129. PubMed ID: 11558855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IIb/IIIa inhibitors in acute myocardial infarction.
    Montalescot G
    Blood Coagul Fibrinolysis; 1999 Feb; 10 Suppl 1():S71-5. PubMed ID: 10070824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
    Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
    Chong PH
    Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction.
    Ferguson JJ; Vaisman D
    Expert Opin Investig Drugs; 2001 Nov; 10(11):1965-76. PubMed ID: 11772300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction.
    Santoro GM; Bolognese L
    Am Heart J; 2001 Feb; 141(2 Suppl):S26-35. PubMed ID: 11174356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.